Chronic lymphoid leukemias: Recent advances in biology and therapy

STEM CELLS

Volumn 13, Issue 1, 1995, Pages 1-21

  Foon, Kenneth A ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

Adult T cell leukemia lymphoma; Chronic lymphocytic leukemia; Follicular lymphoma; Hairy cell leukemia; Large granular lymphocytic leukemia; Mantle cell lymphoma; Prolymphocytic leukemia; S zary cell leukemia

Indexed keywords

ALLOPURINOL; ALPHA INTERFERON; AUTOANTIBODY; CD16 ANTIGEN; CD19 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CD23 ANTIGEN; CD4 ANTIGEN; CD5 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; CHLORAMBUCIL; CHLORMETHINE; CLADRIBINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; INTERLEUKIN 2 RECEPTOR; ISOTRETINOIN; METHOTREXATE; MONOCLONAL ANTIBODY; PENTOSTATIN; PREDNISONE; PSORALEN; RHEUMATOID FACTOR; UNINDEXED DRUG; VINCRISTINE;

ADULT; AGED; AUTOIMMUNITY; BONE MARROW TRANSPLANTATION; CHROMOSOME ABERRATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL SYMPTOM; HAIRY CELL LEUKEMIA; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; HYPERURICEMIA; HYPOGAMMAGLOBULINEMIA; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LARGE GRANULAR LYMPHOCYTE; LEUKEMIA REMISSION; LYMPHOPROLIFERATIVE DISEASE; MALE; MYCOSIS FUNGOIDES; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; PROLYMPHOCYTIC LEUKEMIA; RANDOMIZED CONTROLLED TRIAL; RASH; REVIEW; SEZARY SYNDROME; SPLENECTOMY; T CELL LEUKEMIA; T CELL LYMPHOMA; TOPICAL DRUG ADMINISTRATION; WALDENSTROEM MACROGLOBULINEMIA;

AUTOIMMUNITY; B-LYMPHOCYTES; CHROMOSOME ABERRATIONS; CHROMOSOME DISORDERS; HUMANS; LEUKEMIA, HAIRY CELL; LEUKEMIA, LYMPHOCYTIC; LYMPHOMA; T-LYMPHOCYTES;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN T-LYMPHOTROPIC VIRUS 1;

EID: 0028888659     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.5530130103     Document Type: Article

References (215)

1. Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute‐sponsored working group
2. Chronic lymphocytic leukemia: recommendations for diagnosis, staging and response criteria
3. Genetic factors predisposing to chronic lymphocytic leukemia and to autoimmune disease
4. Radiation‐related leukemia in Hiroshima and Nagaski 1946 to 1964. II. Observations on type‐specific leukemia survivorship and clinical behavior
5. Immunoglobulins on the surface of neoplastic lymphocytes
6. Surface bound immunoglobulins as a cell marker in human lymphoproliferative disease
7. Human B‐cell neoplasms in relation to normal B‐cell differentiation maturation processes
8. Preliminary experience in treating lymphocytic leukemia with antibody to immunoglobulin idiotypes on the cell surfaces
9. Chronic lymphocytic leukemia: clonal origin in a committed B lymphocyte progenitor
10. Chronic lymphocytic leukemia: a monoclonal disease
11. Nonrandom chromosomal aberrations in chronic lymphocytic leukemia revealed by polyclonal B‐cell mitogen stimulation
12. Hierarchy of immunoglobulin gene rearrangements in B‐cell leukemias
13. Developmental hierarchy of immunoglobulin gene rearrangements in human leukemic pre‐B‐cells
14. Immunologic classification of leukemia and lymphoma
15. Infrequent normal B lymphocytes expressed features of B‐chronic lymphocytic leukemia
16. Phenotypic and functional characterization of human Leul (CD5) B cells
17. Normal cellular counterparts of B‐cell chronic lymphocytic leukemia
18. The malignant B cells from B‐chronic lymphocytic leukemia patients release TAC‐soluble inter‐leukin‐2 receptors
19. Pathogenesis of B‐cell malignancies
20. Chronic lymphocytic leukaemia cells activated in vitro reveal cellular changes that characterize B‐pro‐lymphocytic leukaemia and immunocytoma
21. Phorbol ester induces abnormal chronic lymphocytic leukemia cells to express features of hairy cell leukemia
22. Induction of in vitro differentiation and immunoglobulin synthesis of human leukemic B lymphocytes
23. Phenotypic modulation of chronic lymphocytic leukemia cells by phorbol ester: induction of IgM secretion and changes in the expression of B‐cell associated surface antigens
24. Modulation of chronic lymphocytic leukemia cells by phorbol ester: increase in Ia expression, IgM secretion and MLR stimulatory capacity
25. Phorbol ester‐induced differentiation of chronic lymphocytic leukaemia cells
26. T cell helper defect in patients with chronic lymphocytic leukemia
27. Abnormal T‐cell subpopulation function in CLL: excessive suppressor (Tγ) and deficient helper (Tμ) activity with respect to B‐cell proliferation
28. Abnormal T lymphocyte subpopulations in patients with B cell chronic lymphocytic leukemia: an analysis by monoclonal antibody
29. Immunologic studies in chronic lymphocytic leukemia: defective stimulation of T‐cell proliferation in autologous mixed lymphocyte culture
30. Lack of autologous mixed lymphocyte reaction in patients with chronic lymphocytic leukemia: evidence for autoreactive T‐cell dysfunction not correlated with phenotype, karyotype, or clinical status
31. Defective spontaneous and antibody‐dependent cytotoxicity mediated by E‐rosette‐positive and E‐rosette‐negative cells in untreated patients with chronic lymphocytic leukemia: augmentation by in vitro treatment with interferon
32. Deficiency of natural killer cell activity in patients with chronic lymphocytic leukemia
33. Mechanisms of infection in chronic lymphocytic leukemia
34. Immunoglobulin secretory function of B cells from untreated patients with chronic lymphocytic leukemia and hypogammaglobulinemia: role of T‐cells
35. Evidence that large granular lymphocytes from B‐CLL patients with hypogammaglobulinemia down‐regulate B‐cell immunoglobulin synthesis
36. The chronic leukemias: a review of disease manifestations and the aims of therapy
37. Autoimmune thrombocytopenic purpura (“ITP type”) with chronic lymphocytic leukemia
38. Granulocyte antibodies in leukaemic chronic lymphoproliferative disorders
39. Pure red cell aplasia and chronic lymphocytic leukemia
40. The “Ly‐1 B” cell subpopulation in normal immunodefective and autoimmune mice
41. Ly‐1 B cells: functionally distinct lymphocytes that secrete IgM autoantibodies
42. Rheumatoid factor secretion from human Leu‐1+ B cells
43. Human lymphocytes making rheumatoid factor and antibody to ssDNA belong to the Leu‐1+ B cell subset
44. Production of autoantibodies by CD5‐expressing B lymphocytes from patients with chronic lymphocytic leukemia
45. High‐frequency expression of a conserved kappa light‐chain variable‐region gene in chronic lymphocytic leukemia
46. Autoantibody associated kappa light chain variable‐region gene expressed in chronic lymphocytic leukemia with little or no somatic mutation. Implications for etiology and immunotherapy
47. Cytogenetic mapping of the duplicated segment of chromosome 12 in lymphoproliferative disorders
48. Prognostic importance of cytogenetic abnormalities in patients with chronic lymphocytic leukemia
49. Clonal chromosome abnormalities in patients with Waldenström's and CLL‐associated macroglobulinemia: significance of trisomy 12
50. Frequent clonal abnormalities of chromosome band 13q14 in B‐cell chronic lymphocytic leukemia: multiple clones, subclones, and non‐clonal alterations in 82 midwestern patients
51. The chromosome 14 breakpoint in neoplastic B cells with the t(11;14) translocation involves the immunoglobulin heavy chain locus
52. Molecular cloning of the chromosomal breakpoint of B‐cell lymphomas and leukemias with the t(11;14) translocation
53. Multiple recurrent genomic defects in follicular lymphoma. A possible model for cancer
54. The candidate proto‐oncogenebcl‐3 is related to genes implicated in cell lineage determination and cell cycle control
55. Spontaneous remission in chronic lymphocytic leukemia
56. Clinical staging of chronic lymphocytic leukemia
57. Chronic lymphocytic leukemia: new insights into biology and therapy
58. Assessment of marrow trephine in relation to staging in chronic lymphocytic leukaemia
59. Bone marrow biopsy and clinical staging in chronic lymphocytic leukemia
60. Bone marrow histological pattern: the best single prognostic multivariate survival analysis of 329 cases
61. Bone marrow infiltration patterns and their prognostic significance in chronic lymphocytic leukemia: correlations with clinical, immunologic, phenotypic, and cytogenetic data
62. Lymphocyte doubling time in chronic lymphocytic leukemia: analysis of its prognostic significance
63. National Cancer Institute sponsored study of classification of non‐Hodgkin's lymphomas: summary and description of a working formulation for clinical usage
64. Generalized reticular cell sarcoma of lymph nodes associated with lymphocytic leukemia
65. Diffuse histiocytic lymphoma complicating chronic lymphocytic leukemia
66. The lymph node in chronic lymphocytic leukemia
67. Richter's syndrome: a terminal complication of chronic lymphocytic leukemia with distinct clinicopathologic features
68. Genetic relatedness of lymphoid malignancies: transformation of chronic lymphocytic leukemia as a model
69. Prolymphocytic leukaemia
70. B‐lineage prolymphocytic leukemia as a distinct clinico‐pathological entity
71. Chronic lymphocytic leukaemia of T‐cell origin. Immunological and clinical evaluation in 11 patients
72. Prolymphocytic leukaemia of B and T cell type
73. “Prolymphocytoid” transformation of chronic lymphocytic leukaemia
74. Prolymphocytoid transformation of CLL: a clinical and immunological study of 22 cases
75. Prolymphocytic transformation of chronic lymphocytic leukemia
76. Prolymphocytic transformation of chronic lymphocytic leukemia: a report of three cases and review of the literature
77. The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia
78. Chronic lymphocytic leukaemia presenting as a blast cell crisis
79. Acute lymphocytic leukemic transformation of chronic lymphocytic leukemia: substantiation by flow cytometry
80. Acute blast crisis in a patient with chronic lymphocytic leukemia
81. Transformation of chronic lymphocytic leukemia to plasmacytoma
82. The association of chronic lymphocytic leukaemia and multiple myeloma: a study of eleven patients
83. Multiple myeloma and chronic lymphocytic leukemia in a single individual
84. Associated chronic lymphocytic leukemia and multiple myeloma: origin from a single clone
85. Molecular evidence for a single clonal origin in biphenotypic concomitant chronic lymphocytic leukemia and multiple myeloma
86. Effects of chlorambucil and therapeutic decision in initial forms of chronic lymphocytic leukemia (stage A): results of a randomized clinical trial on 612 patients
87. A randomized clinical trial of chlorambucil versus COP in stage B chronic lymphocytic leukemia
88. Treatment of chronic lymphocytic leukemia in advanced stages: a randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine and prednisone
89. Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: long‐term follow‐up of an Eastern Cooperative Oncology Group randomized clinical trial
90. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia
91. 2‐Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia
92. Splenectomy for hematologic depression in lymphocytic lymphoma and leukemia
93. Splenectomy for thrombocytopenia in chronic lymphocytic leukemia
94. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results
95. A new subtype of human T‐cell leukemia virus (HTLV‐II) associated with a T‐cell variant of hairy cell leukemia
96. Prolymphocytic leukemia of B‐cell type: rearranged immunoglobulin (Ig) genes with defective Ig production
97. Clinical and laboratory features of 78 cases T‐prolymphocytic leukemia
98. Cytogenetic studies on prolymphocytic leukemia
99. Chromosome studies in B‐cell prolymphocytic leukemia: a study of nine cases
100. Prolymphocytic leukemia: treatment with combination chemotherapy to include doxorubicin
101. Efficacy of doxorubicin in prolymphocytic leukaemia
102. Complete remission in prolymphocytic leukaemia with the combination chemotherapy CHOP
103. Leukemic reticuloendotheliosis
104. The B‐lymphocyte nature of the hairy cell of leukemic reticuloendotheliosis
105. The phenotype of the neoplastic cells of hairy cell leukemia studies with monoclonal antibodies
106. Antigens on human plasma cells identified by monoclonal antibodies
107. Hairy cell leukemia: a tumor of pre‐plasma cells
108. Immunoglobulin gene rearrangements in hairy cell leukemia
109. Rearrangement and expression of immunoglobulin genes and expression of Tac antigen in hairy cell leukemia
110. T‐lymphocyte variant of hairy‐cell leukemia
111. Hairy cell leukemia: an unusual lymphoproliferative disease—a study of 24 patients
112. Immunodiagnosis of lymphoid malignancies
113. Studies of acid phosphatase isoenzymes in human leukocytes: demonstration of isoenzyme cell specificity
114. The 14q+ marker in hairy cell leukaemia. A cytogenetic study of 15 cases
115. Cytogenetic studies in patients with hairy cell leukemia
116. Hairy cell leukemia: lessons learned in twenty‐five years
117. Serum M‐proteins in hairy cell leukemia, chronic lymphocytic leukemia and free light chain myeloma causing high resolution electrophoresis/immunofixation
118. Severe platelet dysfunction in hairy cell leukemia with improvement after splenectomy
119. Recombinant leukocyte A interferon therapy for hairy‐cell leukemia. Therapeutic and immunologic results
120. Alpha interferon for induction of remission in hairy‐cell leukemia
121. Treatment of hairy cell leukemia with recombinant alpha 2 interferon
122. Hairy cell leukemia: complete remission with pentostatin (2'deoxycoformycin)
123. Deoxycoformycin‐induced immunosuppression in patients with hairy cell leukemia
124. Lasting remissions in hairy‐cell leukemia induced by a single infusion of 2‐chlorodeoxyadenosine
125. The hazards of a chemical laboratory environment—a study of the mortality in two cohorts of Swedish chemists
126. An industry‐wide mortality study of chemical workers occupationally exposed to benzene II. Dose response analyses
127. Soft tissue sarcoma and non‐Hodgkin's lymphoma in relation to phenoxyherbicide and chlorinated phenol exposure in western Washington
128. Non‐Hodgkin's lymphoma and farming: an expanded case‐control study
129. Agricultural herbicide use and risk of lymphoma and soft‐tissue sarcoma
130. Arsenic exposure and mortality: a case‐reference study from a Swedish copper smelter
131. Asbestos exposure and lymphomas of the gastrointestinal tract and oral cavity
132. Non‐Hodgkin's lymphomas among Vietnam veterans
133. Studies of the mortality of A‐bomb survivors. Mortality and radiation dose, 1950–1974
134. Chromosome studies in the non‐Hodgkin's lymphomas: the role of the 14;18 translocation
135. Mantle cell lymphoma. A proposal for unification of morphologic, immunologic and molecular data
136. Non‐Hodgkin's lymphomas of mantle zone origin
137. Intermediate lymphocytic lymphoma: clinical and pathologic features of a recently characterized subtype of non‐Hodgkin's lymphoma
138. Non‐Hodgkin's lymphomas with t(11;14) (113;q32): a subset of mantle zone/intermediate lymphocytic lymphoma?
139. Bcl‐1, t(11;14), and mantle cell‐derived lymphomas
140. Characterization of a candidate bcl‐1 gene
141. Mantle zone lymphoma. A clinicopathologic study of 22 cases
142. Lymphocytic lymphoma of intermediate differentiation. Morphologic and immunophenotypic spectrum and clinical correlations
143. No initial therapy for stage III and IV non‐Hodgkin's lymphoma of favorable histologic types
144. Non‐Hodgkin's lymphomas: characteristics of long‐term survivors following conservative treatment
145. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment
146. Prolonged disease‐free survival after autologous bone marrow transplantation in patients with non‐Hodgkin's lymphomas with a poor prognosis
147. Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis
148. Centrocytic lymphoma: a distinct clinicopathologic and immunologic entity. A multiparameter study of 18 cases at diagnosis and relapse
149. Adult T‐cell leukemia: clinical and hematologic features of 16 cases
150. Clinical course of retrovirus associated adult T‐cell lymphoma in the United States: staging, evaluation, and management
151. Adult T‐cell lymphoma/leukaemia in blacks from the West Indies
152. Clinical features. In: Broder S, moderator. T‐cell lymphoproliferative syndrome associated with human T‐cell leukemia/lymphoma virus
153. The human type‐C retrovirus HTLV in blacks from the Caribbean region, and relationship to adult T‐cell leukemia/lymphoma
154. Natural antibodies to the human T cell lymphoma virus in patients with T cell lymphomas
155. Antibodies in human sera reactive against an internal structural protein of human T‐cell lymphoma virus
156. Altered cellular gene expression in human retro‐viral‐associated leukemogenesis
157. The family of human T‐lymphotropic leukemia viruses: HTLV‐I as the cause of adult T cell leukemia and HTLV‐III as the cause of acquired immunodeficiency syndrome
158. Human T‐cell leukemia/lymphoma virus: epidemiology and relationship to human malignancy
159. Human T‐cell leukemia virus (HTLV‐I) antibodies in Africa
160. Type C virus particles in a cord T‐cell line derived by co‐cultivating normal human leukocytes and human leukaemic T cells
161. Transformation of human umbilical cord blood T cells by human T‐cell leukemia/lymphoma virus
162. Functional and phenotypic studies of Japanese adult T cell leukemia cells
163. Functional and phenotypic comparison of human T cell leukemia/lymphoma virus positive, adult T cell leukemia with human T cell leukemia/lymphoma virus negative, Sézary leukemia, and their distinction using anti‐Tac
164. T‐cell receptor gene rearrangements as markers of lineage and clonality in T cell neoplasms
165. Rearrangements of genes for the antigen receptor on T‐cells as markers of lineage and clonality in human lymphoid neoplasms
166. T‐cell receptor gene rearrangements as clinical markers of human T‐cell lymphomas
167. Rearrangement of the gene for the beta chain of the T‐cell receptor in T‐cell chronic lymphocytic leukemia and related disorders
168. Chromosomal aberrations in adult T cell leukemia: relationship to the clinical severity
169. Chromosomal abnormalities in adult T‐cell leukemia/lymphoma (ATL)
170. Specific abnormalities of chromosome 14 in patients with acute type of adult T‐cell leukemia/lymphoma
171. Chromosome abnormalities, sister chromatid exchanges, and cell cycle analysis in phyto‐hemagglutinin‐stimulated adult T‐cell leukemia lymphocytes
172. Cytogenetic studies in human T‐cell lymphoma virus (HTLV) positive leukemia‐lymphoma in the United States
173. Chromosome aberrations and clinical features of adult T cell leukemia‐lymphoma not associated with human T cell leukemia virus type I
174. Abnormalities of chromosome 7q and Tac expression in T cell leukemias
175. Diagnostic criteria and classification of clinical subtypes of adult T‐cell leukemia‐lymphoma. A report from the Lymphoma Study Group
176. A proposal for smoldering adult T‐cell leukemia: a clinicopathologic study of five cases
177. Therapy of patients with human T‐cell lymphotrophic virus I‐induced adult T‐cell leukemia with anti‐Tac, a monoclonal antibody to the receptor for interleukin‐2
178. Recombinant interferon beta and gamma in the treatment of adult T‐cell leukemia
179. Alpha‐interferon treatment for adult T cell leukemia: low levels of circulating alpha‐interferon and its clinical effectiveness
180. Successful chemotherapy with deoxycoformycin in adult T‐cell lymphoma‐leukemia
181. Cutaneous T‐cell lymphoma: a review
182. Phenotypic characterization of cutaneous T‐cell lymphoma
183. Cutaneous T cell lymphoma: characterization by monoclonal antibodies
184. Immunologic classification of lymphocytic leukemias based on monoclonal antibody‐defined cell surface antigens
185. The Sézary syndrome: a malignant proliferation of helper T cells
186. Phenotypic characterization of skin‐infiltrating T cells in cutaneous T‐cell lymphoma: comparison with benign cutaneous T‐cell infiltrates
187. Clinical implications of cytogenetic studies in cutaneous T‐cell lymphoma (CTCL)
188. Mycosis fungoides. Survival, prognostic features, response to therapy and autopsy findings
189. Erythrodermic avec presence de cellules monstrueuses dan le derme et dans le lang circulant
190. Mycosis fungoides with extracutaneous dissemination: a distinct clinicopathologic entity
191. Chronic herpes simplex infection in cutaneous T‐cell lymphomas
192. Herpes zoster‐varicella in cutaneous T‐cell lymphomas
193. Recombinant leukocyte A interferon: an active agent in advanced cutaneous T‐cell lymphoma
194. Treatment of cutaneous T‐cell lymphoma (mycosis fungoides) with 13‐cis‐retinoic acid
195. Leukapheresis in the treatment of Sézary syndrome
196. Successful management of the Sézary syndrome. Mobilization and removal of extravascular neoplastic T cells by leukapheresis
197. Treatment of cutaneous T‐cell lymphoma by extracorporeal photochemotherapy. Preliminary results
198. 2'deoxycoformycin (CDF) induced remission in advanced cutaneous T‐cell lymphomas (CTCL)
199. Radioimmunodetection and radioimmunotherapy of cutaneous T‐cell lymphomas using a 131 I‐labeled monoclonal antibody: an Illinois Cancer Council Study
200. T gamma‐lymphopro‐liferative disorders in humans and experimental animals: a review of the clinical, cellular and functional characteristics
201. Chronic T cell lymphocytosis: a review of 21 cases
202. A case of chronic lymphocytic leukemia with properties characteristic of natural killer cells
203. Chromosome studies in patients with T‐CLL chronic lymphocytic leukemia and expansions of granular lymphocytes
204. Leukemia of large granular lymphocytes: association with clonal chromosomal abnormalities and autoimmune neutropenia, thrombocytopenia, and hemolytic anemia
205. Receptors for immunoglobulins on resting and activated human T cells
206. Cells with Fc receptors from normal donors suppress granulocyte macrophage colony formation
207. Polyarthritis and neutropenia associated with circulating large granular lymphocytes
208. Rheumatoid arthritis associated with expanded populations of granular lymphocytes
209. Erythrophagocytic T gamma lymphoma: a clinicopathologic entity resembling malignant histiocytosis
210. Characterization of two patients with lymphomas of large granular lymphocytes
211. Natural killer and suppressor T‐cell chronic lymphocytic leukemia
212. Cell mediated inhibition of erythropoiesis and megaloblastic anemia in T‐cell chronic lymphocytic leukemia
213. Treatment of large granular lymphocyte leukemia with oral low‐dose methotrexate
214. Cyclosporin reverses agranulocytosis associated with large granular lymphocyte proliferation